In short
This article explores the use of CART 19/22 T Cells in clinical trials for treating refractory/relapsed acute lymphoblastic leukemia (ALL) in children, adolescents, and young adults. The trials aim to evaluate the safety and feasibility of this innovative therapy for patients who have not responded to conventional treatments. The study focuses on two types of CAR T-cell therapies: autologous CART-19/22 for B-cell ALL and allogeneic CART-NKG2D for T-cell ALL.
At a glance
- Study Type
- Phase I, open-label, prospective, single-center, two-armed, non-randomized trial
- Target Population
- Children, adolescents, and young adults (< 30 years) with refractory/relapsed acute lymphoblastic leukemia
- Treatment Arms
- Arm A: Autologous CART-19/22 for B-ALL; Arm B: Allogeneic CART-NKG2D for T-ALL
- Primary Objectives
- Safety and feasibility of CART cell therapies
- Secondary Objectives
- Expression of target proteins, CAR T-cell persistence, cytokine profiles, overall response rates
- Key Inclusion Criteria
- Age < 30 years, adequate organ function, refractory/relapsed ALL not responding to conventional chemotherapy
- Key Exclusion Criteria
- Active infections, significant cardiac issues, CNS-3 disease, uncontrolled seizures, pregnancy
- Administration
- Intravenous infusion of CAR T cells over multiple days
What is CART 19/22 T Cells?
CART 19/22 T Cells is an innovative form of cell therapy being studied for the treatment of refractory or relapsed acute lymphoblastic leukemia (ALL) in children, adolescents, and young adults. This therapy is a type of CAR T-cell therapy, which stands for Chimeric Antigen Receptor T-cell therapy. It's a personalized treatment that uses a patient's own immune cells to fight cancer.
How It Works
CART 19/22 T Cells are designed to target two specific proteins found on the surface of leukemia cells: CD19 and CD22. Here's a simplified explanation of how it works:
- T cells (a type of immune cell) are collected from the patient's blood.
- These T cells are genetically modified in a laboratory to produce special receptors on their surface called chimeric antigen receptors (CARs).
- The modified T cells are then multiplied in the lab.
- The patient receives the modified T cells back through an intravenous (IV) infusion.
- Once in the body, these CART 19/22 T cells can recognize and attack cancer cells that have CD19 and/or CD22 on their surface.
Target Patients
This therapy is being studied for patients who meet the following criteria:
- Children, adolescents, and young adults (under 30 years old at diagnosis or relapse)
- Diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) that is CD19+ and/or CD22+
- Have relapsed (cancer has returned) or refractory (cancer is not responding to standard treatments) disease
- No other curative therapy options available
It's important to note that this treatment is still in the research phase and is not yet widely available outside of clinical trials.
Treatment Process
The treatment process for CART 19/22 T cells involves several steps:
- Preparation: Patients undergo tests to ensure they're eligible for the treatment.
- Cell Collection: T cells are collected from the patient's blood through a process called leukapheresis.
- Cell Modification: The collected T cells are sent to a laboratory where they are genetically modified and multiplied.
- Conditioning Chemotherapy: Patients may receive chemotherapy to prepare their body for the CAR T-cell infusion.
- Infusion: The modified CART 19/22 T cells are given back to the patient through an IV infusion. This is typically done in two doses, separated by 72 hours.
- Monitoring: Patients are closely monitored for several weeks after the infusion for potential side effects and to assess the treatment's effectiveness.
Potential Benefits
CART 19/22 T cell therapy offers several potential benefits for patients with refractory or relapsed ALL:
- It provides a treatment option for patients who have exhausted other therapies.
- By targeting both CD19 and CD22, it may be effective against a broader range of leukemia cells, including those that have lost CD19 expression.
- It's a personalized therapy using the patient's own immune cells, potentially reducing the risk of rejection.
- It may lead to long-lasting remissions in some patients.
Safety Considerations
While CART 19/22 T cell therapy shows promise, it's important to be aware of potential side effects:
- Cytokine Release Syndrome (CRS): This is a common side effect that can cause fever, low blood pressure, and difficulty breathing. It's usually manageable but can be severe in some cases.
- Neurological Effects: Some patients may experience confusion, seizures, or other neurological symptoms.
- B-cell Aplasia: The therapy may also destroy healthy B cells, leading to a weakened immune system.
Patients are closely monitored for these and other side effects during and after treatment.
Ongoing Research
CART 19/22 T cell therapy is currently being studied in clinical trials to assess its safety and effectiveness. Researchers are looking at various aspects, including:
- How long the modified T cells persist in the patient's body
- The overall response rate to the treatment
- The therapy's impact on patients' quality of life
- Potential improvements to the treatment process
As research continues, we may gain a better understanding of how to optimize this therapy and identify which patients are most likely to benefit from it.